Form 4: Revance Therapeutics CLO & GC, Dwight Moxie, Reports Vesting of Performance-Based Restricted Stock Units

Dwight Moxie, CLO & GC of Revance Therapeutics, reports the vesting of performance-based restricted stock units based on achievement of revenue goals.

Summary

• On February 3, 2025, Dwight Moxie, CLO & GC of Revance Therapeutics, reported the vesting of 5,979 shares of common stock.
• These shares resulted from the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023.
• The vesting was contingent upon the achievement of revenue goals from January 1, 2024, through December 31, 2024, and the reporting person's continuous service through the vesting date.
• Following the transaction, Moxie directly owns 143,794 shares of Revance Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs suggests that the company has met some of its performance targets, which is a positive indicator. However, it's a routine filing and doesn't provide enough information to make a strong positive assessment.

Positives

• The vesting of PSUs indicates that Revance Therapeutics achieved a portion of its revenue goals for the period of January 1, 2024, through December 31, 2024.
• Dwight Moxie's continued service through the vesting date is a positive sign of stability in the company's leadership.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry. It reflects the company's performance against pre-defined goals and its commitment to incentivizing key personnel.

Comparison to Industry Standards

• Performance-based equity compensation is a standard practice in the biopharmaceutical industry to align executive incentives with company performance.
• Companies like Allergan (now AbbVie) and Evolus also utilize similar compensation structures to incentivize their executives based on achieving specific milestones and revenue targets.
• The vesting of PSUs based on revenue goals is a common metric used to measure the success of commercialization efforts in the pharmaceutical sector.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, indicating that the company is achieving its revenue goals.
• Employees may be motivated by the company's performance and the alignment of executive compensation with company success.

Key Dates

Keywords

Revance Therapeutics, Dwight Moxie, Form 4, Vesting, Performance-Based Restricted Stock Units, PSUs, Revenue Goals, Common Stock, Beneficial Ownership